FINWIRES · TerminalLIVE
FINWIRES

Aardvark Therapeutics' Investigational New Drug Application for ARD-101 Put on Clinical Hold by FDA

By

Aardvark Therapeutics (AARD) said late Thursday the US Food and Drug Administration placed a full clinical hold on its investigational new drug application for ARD-101 to treat hyperphagia associated with Prader-Willi Syndrome.

The hold applies to all ongoing clinical studies under the IND, the company said, adding that it is in discussions with the FDA for resolution of the clinical hold and to fix a path forward for the drug candidate.

The company also plans to unblind clinical data from the HERO and OLE trials to assess the totality of efficacy and safety data, according to the company.

The company said it had $91.2 million in cash and cash equivalents as of March 31, adequate to fund operations into mid-2027.

Related Articles

Australia

Sky Harbour Q1 Loss Narrows, Revenue Rises; Shares Fall After Hours

Sky Harbour Group (SKYH) reported a Q1 loss late Thursday of $0.16 per diluted share, narrowing from a loss of $0.19 a year earlier.Analysts polled by FactSet expected a loss of $0.13.Revenue in the three months ended March 31 rose to $8.73 million from $5.59 million a year earlier.Analysts surveyed by FactSet expected $9.8 million.Sky Harbour shares fell 4.9% in after-hours trading.

$SKYH
Australia

KinderCare Learning Q1 Adjusted Earnings Fall, Revenue Rises; Shares Drop After Hours

KinderCare Learning (KLC) reported Q1 adjusted earnings late Thursday of $0.04 per diluted share, down from $0.23 a year earlier.Analysts surveyed by FactSet expected a loss of $0.01.Revenue in the three months ended April 4 rose to $672.5 million from $668.2 million a year earlier.Analysts surveyed by FactSet expected $669.1 million.The company boosted full-year adjusted EPS guidance to $0.15 to $0.25 from the previous forecast of $0.10 to $0.20. It affirmed the revenue outlook of $2.7 billion to $2.75 billion.Analysts expect EPS of $0.15 on revenue of $2.71 billion.KinderCare shares fell 6.2% in after-hours trading.

$KLC
Australia

Globant Q1 Adjusted EPS Unchanged, Revenue Declines; Q2 Guidance Set

Globant (GLOB) reported Q1 adjusted earnings late Thursday of $1.50 per diluted share, unchanged from a year earlier.Analysts polled by FactSet expected $1.49.Revenue for the three months ended March 31 was $607.1 million, down from $611.1 million a year earlier.Analysts surveyed by FactSet expected $601.7 million.For Q2, the company expects adjusted EPS of $1.45 to $1.55 on revenue of $610 million to $616 million. Analysts expect EPS of $1.54 on revenue of $613.3 million.For the full-year 2026, the company expects adjusted EPS of $6.10 to $6.50 on revenue of $2.46 billion to $2.51 billion. Analysts expect EPS of $6.24 on revenue of $2.48 billion.

$GLOB